Physician profile
Chirag Patel
NPI 1457307142
$3,339.00
in general payments reported to CMS, 2019-2025
18 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $15.89 · 2021: $213 · 2022: $427 · 2023: $325 · 2024: $549 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Travel and Lodging: $555 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.36 |
| Travel and Lodging | $554.93 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.07 | 2019-2025 | |
| Janssen Biotech, INC. | $907.45 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $198.45 | 2021-2023 | Zeposia |
| Pfizer INC. | $155.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $133.83 | 2021-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2022 | |
| Intercept Pharmaceuticals, INC. | $122.74 | 2021-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $106.31 | 2019 | |
| Gilead Sciences, INC. | $73.21 | 2019-2025 | |
| Teleflex LLC | $66.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.66 | 2021-2023 | Entyvio |
| Qol Medical, LLC | $35.12 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $23.82 | 2024 | Voquezna |
| Genzyme Corporation | $22.10 | 2025 | |
| Mirum Pharmaceuticals, INC. | $20.81 | 2025 | Livmarli |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Novo Nordisk INC | $18.33 | 2025 | Wegovy |
| Romark Laboratories, Lc | $6.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.